In a study involving 989 non-renal patients with CAD [42], HCMV seropositivity was independently associated with a 3.2-fold increase in risk of future cardiac death only in patients with high IL-6 levels, whereas in individuals without IL-6 elevation, HCMV had no effect on cardiac mortality. This evidence concerns the gene IL6 and coronary artery disorder.